Mopuri et al., 2023 - Google Patents
High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelopeMopuri et al., 2023
View HTML- Document ID
- 4897580710116491268
- Author
- Mopuri R
- Welbourn S
- Charles T
- Ralli-Jain P
- Rosales D
- Burton S
- Aftab A
- Karunakaran K
- Pellegrini K
- Kilembe W
- Karita E
- Gnanakaran S
- Upadhyay A
- Bosinger S
- Derdeyn C
- Publication year
- Publication venue
- PLoS Pathogens
External Links
Snippet
A protective HIV-1 vaccine has been hampered by a limited understanding of how B cells acquire neutralizing activity. Our previous vaccines expressing two different HIV-1 envelopes elicited robust antigen specific serum IgG titers in 20 rhesus macaques; yet …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wilson et al. | Tools to therapeutically harness the human antibody response | |
| Doria-Rose et al. | New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency | |
| Crowe | Principles of broad and potent antiviral human antibodies: insights for vaccine design | |
| Moody et al. | HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages | |
| Zhu et al. | Somatic populations of PGT135–137 HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatics | |
| Verkoczy et al. | Human Ig knockin mice to study the development and regulation of HIV‐1 broadly neutralizing antibodies | |
| Phad et al. | Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses | |
| Chen et al. | A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design | |
| Kreer et al. | Exploiting B cell receptor analyses to inform on HIV-1 vaccination strategies | |
| Kamdem Toukam et al. | Targeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus | |
| Hou et al. | Sequential immunization induces strong and broad immunity against all four dengue virus serotypes | |
| Waltari et al. | 5′ rapid amplification of cDNA ends and illumina MiSeq reveals B cell receptor features in healthy adults, adults with chronic HIV-1 infection, cord blood, and humanized mice | |
| Han et al. | Coupling of single molecule, long read sequencing with IMGT/HighV-QUEST analysis expedites identification of SIV gp140-specific antibodies from scFv phage display libraries | |
| Fisher et al. | Oral Immunization with HIV-1 Envelope SOSIP trimers elicits systemic immune responses and cross-reactive anti-V1V2 antibodies in non-human primates | |
| Welles et al. | Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4 | |
| Spencer et al. | Polyfunctional Tier 2–Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor | |
| Hicar et al. | Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations | |
| Sholukh et al. | Isolation of monoclonal antibodies with predetermined conformational epitope specificity | |
| Mopuri et al. | High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelope | |
| Lewis et al. | CTLA-4 blockade, during HIV virus-like particles immunization, alters HIV-specific B-cell responses | |
| Zhang et al. | The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development | |
| Grimm et al. | Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies | |
| Xu et al. | Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer | |
| Heydarchi et al. | Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env | |
| Chang et al. | RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines |